Biointron AbDrop™ & Cyagen HUGO-Ab™

Biointron's AbDrop™ platform leverages the microfluidic technology as the screening method to generate droplets encapsulating individual plasma cells.

Microfluidic technology for antibody development involves manipulating small fluid volumes within microfabricated channels, offering precise control over experimental conditions and enabling high-throughput testing. This technology reduces reagent consumption, enhances reaction kinetics, and integrates multiple development steps into a single device, improving efficiency, speed, and precision in antibody production and screening.

Transgenic mice with human immunoglobulin loci can produce a wide range of human-like antibodies. Isolating single B cells from these mice allows for capturing this diversity at the individual cell level, leading to the discovery of unique and highly specific antibodies.

Single B cell techniques can quickly identify and clone antibodies, accelerating the overall development process when combined with the pre-existing diversity and maturation from transgenic mice.

This combination can also provide comprehensive coverage of epitopes on target antigens, enhancing the chances of identifying effective therapeutic antibodies.

Cyagen has developed TurboKnockout® gene editing technology to serve as an upgraded version of ES targeting by retaining the advantages of traditional ES targeting [https://www.cyagen.com/us/en/community/technical-bulletin/turboknockout-technology.html], such as maturity, precise modification, and stable results. Additionally, TurboKnockout® reduces the breeding time by two generations, shortening the cycle to as little as 4 months. This makes it the preferred method for constructing complex models, such as those requiring large segment gene modifications.